US-based inhaled medicines provider Genoa Pharmaceuticals in collaboration with McMaster University has demonstrated advantages of the inhaled aerosol pirfenidone (GP-101) in the treatment of pulmonary fibrosis.
The findings showed that small inhaled doses yielding high peak, short duration lung pirfenidone concentrations provide statistically greater anti-fibrotic efficacy than higher oral doses resulting in low peak drug exposure by using the in vivo model of bleomycin-induced pulmonary fibrosis.
Genoa Pharmaceuticals founder, president and chief scientific officer Mark Surber said for IPF treatment to be successful, sufficient drug must first be delivered to the lung.
Read the entire article at:
For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com